Login
Companies $KOD
$101.46 +$0.73 (0.73%) After hours
Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

kodiak.com

What Do They Do?

Develops retinal disease medicines for patients with retinal vascular diseases and macular edema caused by inflammation.

How Do They Make Money?

No revenue reported yet.

Who Are Their Customers?

The candidates target patients with diabetic retinopathy, wet AMD and retinal vein occlusion, as well as macular edema caused by inflammation.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −8% (Loss)
vs −$61.5M in Q3 FY2025
  • Nov 12, 2026 Two investigational medicines met DAYBREAK’s primary endpoints Zenkuda and tabirafusp-ted met the vision primary endpoint in the wet AMD study.
  • Sep 28, 2026 Zenkuda and tabirafusp-ted met DAYBREAK primary endpoints Both achieved non-inferiority in vision gains compared with aflibercept at year one.

A new inflammation-focused program The older report described retinal vascular medicines and triplet medicines for dry AMD and glaucoma; the latest adds a candidate for macular edema caused by inflammation.

Who Do They Compete With?

Competes with Avastin, Eylea, Eylea HD, Vabysmo, Lucentis, Roche, and Regeneron

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support